» Articles » PMID: 18621920

Anti-inflammatory ApoA-I-mimetic Peptides Bind Oxidized Lipids with Much Higher Affinity Than Human ApoA-I

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2008 Jul 16
PMID 18621920
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

4F is an anti-inflammatory, apolipoprotein A-I (apoA-I)-mimetic peptide that is active in vivo at nanomolar concentrations in the presence of a large molar excess of apoA-I. Physiologic concentrations ( approximately 35 microM) of human apoA-I did not inhibit the production of LDL-induced monocyte chemotactic activity by human aortic endothelial cell cultures, but adding nanomolar concentrations of 4F in the presence of approximately 35 microM apoA-I significantly reduced this inflammatory response. We analyzed lipid binding by surface plasmon resonance. The anti-inflammatory 4F peptide bound oxidized lipids with much higher affinity than did apoA-I. Initially, we examined the binding of PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine) and observed that its oxidized products bound 4F with an affinity that was approximately 4-6 orders of magnitude higher than that of apoA-I. This high binding affinity was confirmed in studies with defined lipids and phospholipids. 3F-2 and 3F(14) are also amphipathic alpha-helical octadecapeptides, but 3F-2 inhibits atherosclerosis in mice and 3F(14) does not. Like 4F, 3F-2 also bound oxidized phospholipids with very high affinity, whereas 3F(14) resembled apoA-I. The extraordinary ability of 4F to bind pro-inflammatory oxidized lipids probably accounts for its remarkable anti-inflammatory properties.

Citing Articles

Oxidised phosphatidylcholine induces sarcolemmal ceramide accumulation and insulin resistance in skeletal muscle.

Zemski Berry K, Garfield A, Jambal P, Zarini S, Perreault L, Bergman B Diabetologia. 2024; 67(12):2819-2832.

PMID: 39347985 DOI: 10.1007/s00125-024-06280-8.


Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions.

Mitsis A, Myrianthefs M, Sokratous S, Karmioti G, Kyriakou M, Drakomathioulakis M Biomedicines. 2024; 12(8).

PMID: 39200135 PMC: 11351818. DOI: 10.3390/biomedicines12081670.


High-density lipoprotein mimetic nano-therapeutics targeting monocytes and macrophages for improved cardiovascular care: a comprehensive review.

Zhen J, Li X, Yu H, Du B J Nanobiotechnology. 2024; 22(1):263.

PMID: 38760755 PMC: 11100215. DOI: 10.1186/s12951-024-02529-x.


Antioxidant and Anti-Inflammatory Functions of High-Density Lipoprotein in Type 1 and Type 2 Diabetes.

Denimal D Antioxidants (Basel). 2024; 13(1).

PMID: 38247481 PMC: 10812436. DOI: 10.3390/antiox13010057.


High-Density Lipoprotein in Metabolic Disorders and Beyond: An Exciting New World Full of Challenges and Opportunities.

Zvintzou E, Xepapadaki E, Skroubis G, Mparnia V, Giannatou K, Benabdellah K Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375802 PMC: 10300751. DOI: 10.3390/ph16060855.


References
1.
Handattu S, Garber D, Horn D, Hughes D, Berno B, Bain A . ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem. 2006; 282(3):1980-8. DOI: 10.1074/jbc.M606231200. View

2.
Kruger A, Peterson S, Turkseven S, Kaminski P, Zhang F, Quan S . D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation. 2005; 111(23):3126-34. DOI: 10.1161/CIRCULATIONAHA.104.517102. View

3.
Gugiu B, Mouillesseaux K, Duong V, Herzog T, Hekimian A, Koroniak L . Protein targets of oxidized phospholipids in endothelial cells. J Lipid Res. 2007; 49(3):510-20. DOI: 10.1194/jlr.M700264-JLR200. View

4.
Navab M, Hama S, Anantharamaiah G, Hassan K, Hough G, Watson A . Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000; 41(9):1495-508. View

5.
Epand R, Epand R, Sayer B, Datta G, Chaddha M, Anantharamaiah G . Two homologous apolipoprotein AI mimetic peptides. Relationship between membrane interactions and biological activity. J Biol Chem. 2004; 279(49):51404-14. DOI: 10.1074/jbc.M408581200. View